Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Daningrat W.O.D.; Paramaiswari W.T.; Putri H.F.M.; Aanensen D.; Safari D.
Daningrat, Wa Ode Dwi (57254035500); Paramaiswari, Wisiva Tofriska (57221097580); Putri, Hanifah Fajri Maharani (57898586800); Aanensen, David (6507460526); Safari, Dodi (23493586700)
57254035500; 57221097580; 57898586800; 6507460526; 23493586700
Prevalence, serotype distribution, and antimicrobial susceptibility profile of Streptococcus pneumoniae in Sea Nomad children under 5 years of age in Wakatobi, Southeast Sulawesi, Indonesia: A cross-sectional study
2024
Journal of Global Antimicrobial Resistance
39
93
99
6
0
Centre for Genomic Pathogen Surveillance, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Master's Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Cluster of Infectious Diseases and Immunology. Indonesian Medical Education and Research Institute (IMERI), Indonesia; Eijkman Research Centre for Molecular Biology, National Research and Innovation Agency, West Java, Cibinong, Indonesia
Daningrat W.O.D., Centre for Genomic Pathogen Surveillance, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Paramaiswari W.T., Master's Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Cluster of Infectious Diseases and Immunology. Indonesian Medical Education and Research Institute (IMERI), Indonesia; Putri H.F.M., Cluster of Infectious Diseases and Immunology. Indonesian Medical Education and Research Institute (IMERI), Indonesia; Aanensen D., Centre for Genomic Pathogen Surveillance, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Safari D., Eijkman Research Centre for Molecular Biology, National Research and Innovation Agency, West Java, Cibinong, Indonesia
Objective: Indonesia commenced the nationwide introduction of pneumococcal conjugate vaccine (PCV) in 2022. Pre-vaccine Streptococcus pneumoniae data from across the country could be critical to enable vaccine impact evaluation in the future. This study evaluates colonization prevalence, factors associated with colonization, serotype distribution, and the antimicrobial susceptibility profile of S. pneumoniae. Methods: Children under 5 years of age were enrolled from Bajau tribe settlements in Wakatobi, southeast Sulawesi, Indonesia, from October 2018 to February 2019. Nasopharyngeal swab specimens were analysed by culture, and isolates were serotyped using sequential multiplex polymerase chain reaction. Antibiotic susceptibility was performed by the disk diffusion method. Multivariable logistic regression was performed for risk factor analysis. Results: A total of 499 NP swab specimens were collected; 61.9% were colonized with S. pneumoniae and 48.9% of the isolates were of PCV13-vaccine type. The most common serotypes were 23F, 6B, 19F, and 6A at 13.2%, 9.8%, 8.9%, and 8.0%, respectively. Exposure to cigarette smoke in the household and runny nose were significant risk factors for colonization, with aORs of 1.6 (95% confidence interval: 1.1–2.3) and 2.1 (95% confidence interval: 1.4–3.3), respectively. Conclusions: The findings of this study may contribute to baseline pre-vaccine data in Indonesia that would be critical for the impact evaluation of vaccines. © 2024 The Authors
Indonesia; Nasopharyngeal carriage rate; PCV introduction; Sea Nomads; Streptococcus pneumoniae
azithromycin; chloramphenicol; cigarette smoke; clindamycin; cotrimoxazole; erythromycin; oxacillin; Pneumococcus vaccine; tetracycline; vancomycin; antibiotic resistance; antibiotic sensitivity; Article; bacterial colonization; child; controlled study; cross-sectional study; disk diffusion; female; household; human; human tissue; Indonesia; major clinical study; male; multiplex polymerase chain reaction; nasopharyngeal swab; nonhuman; preschool child; prevalence; rhinorrhea; risk factor; serotype; serotyping; Streptococcus pneumoniae; swabbing
Elsevier Ltd
22137165
39197656
Article
Q2
880
5406